Werewolf Therapeutics (HOWL) Free Cash Flow (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Free Cash Flow of $6.6 million for Q2 2026, up 143.72% year-over-year from $2.7 million in Q2 2025, and up 162.56% on a QoQ basis from -$10.6 million in Q1 2026.
Werewolf Therapeutics (HOWL) Free Cash Flow (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Free Cash Flow for 7 years, with the latest figure at $6.6 million in Q2 2026.
- Free Cash Flow for Q2 2026 came in at $6.6 million, up 143.72% year-over-year; the trailing twelve-month figure through Jun 2026 was -$30.1 million (up 50.54% YoY), and the FY2025 annual result was -$60.3 million, down 6.82% from the prior year.
- Free Cash Flow climbed to $6.6 million in Q2 2026, from -$10.6 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $6.6 million in Q2 2026 and troughed at -$18.9 million in Q1 2025.
- A 5-year average of -$11.0 million and a median of -$12.4 million in 2022 frame the typical range for Free Cash Flow.
- The widest annual swing landed in 2023, when Free Cash Flow plunged 1656.8%; it then jumped 143.72% in 2026.
- A 5-year view of Free Cash Flow shows it stood at -$12.4 million in 2022, then jumped by 61.39% to -$4.8 million in 2023, then plunged by 200.54% to -$14.4 million in 2024, then advanced by 23.31% to -$11.0 million in 2025, then jumped by 160.13% to $6.6 million in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were $6.6 million in Q2 2026, -$10.6 million in Q1 2026, and -$11.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | 6.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.63 Mn |
| Jun 30, 2026 | 6.63 Mn |
| Mar 31, 2026 | -10.60 Mn |
| Mar 31, 2026 | -10.60 Mn |
| Dec 31, 2025 | -11.02 Mn |
| Dec 31, 2025 | -11.02 Mn |
| Sep 30, 2025 | -15.16 Mn |
| Sep 30, 2025 | -15.16 Mn |
| Jun 30, 2025 | -15.16 Mn |
| Jun 30, 2025 | -15.16 Mn |
| Mar 31, 2025 | -18.95 Mn |
| Mar 31, 2025 | -18.95 Mn |
| Dec 31, 2024 | -14.38 Mn |
| Dec 31, 2024 | -14.38 Mn |
| Sep 30, 2024 | -12.47 Mn |
| Sep 30, 2024 | -12.47 Mn |
| Jun 30, 2024 | -14.19 Mn |
| Jun 30, 2024 | -14.19 Mn |
| Mar 31, 2024 | -15.41 Mn |
| Mar 31, 2024 | -15.41 Mn |